Elevated plasma stromal-cell-derived factor-1 protein levels correlate with severity in patients with community-acquired pneumonia

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Tsai, Ping Kun ^a,b,c   Hsieh, Ming Ju ^c,d   Wang, Hsiang Ling ^c,e   Chou, Ming Chih ^c   Yang, Shun Fa ^c,f   Yeh, Chao Bin ^b,c  

^a Zuoying Armed Force General Hospital   (Taiwan)

^b University Hospital   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e NATIONAL TAICHUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, HUMAN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PROTEIN EXPRESSION; BLOOD; CASE CONTROL STUDY; COMMUNITY-ACQUIRED INFECTIONS; MIDDLE AGED; PNEUMONIA;

CASE-CONTROL STUDIES; CHEMOKINE CXCL12; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 84908374828     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/829706     Document Type: Article

References (33)

1. Lutfiyya M. N., Henley E., Chang L. F., Reyburn S. W., Diagnosis and treatment of community-acquired pneumonia. American Family Physician 2006 73 3 442 450 2-s2.0-32244442157
2. Waterer G. W., Rello J., Wunderink R. G., Management of community-acquired pneumonia in adults. The American Journal of Respiratory and Critical Care Medicine 2011 183 2 157 164 10.1164/rccm.201002-0272CI 2-s2.0-78751682782
3. Ramirez J. A., Anzueto A. R., Changing needs of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 2011 66 supplement 3 iii3 iii9 10.1093/jac/dkr094 2-s2.0-79955021835
4. Department of Statistics of Ministry of Health and Welfare in Taiwan, Causes of Death in Taiwan, 2012 2013 Taipei, Taiwan Ministry of Health and Welfare in Taiwan
5. Coelho L., Póvoa P., Almeida E., Fernandes A., Mealha R., Moreira P., Sabino H., Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Critical Care 2007 11, article R92 10.1186/cc6105 2-s2.0-34648828385
6. Thiem U., Niklaus D., Sehlhoff B., Stückle C., Heppner H. J., Endres H. G., Pientka L., C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. Age and Ageing 2009 38 6 693 697 10.1093/ageing/afp164 2-s2.0-70350697886
7. Kim J. H., Seo J. W., Mok J. H., Kim M. H., Cho W. H., Lee K., Kim K. U., Jeon D., Park H.-K., Kim Y. S., Kim H. H., Lee M. K., Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberculosis and Respiratory Diseases 2013 74 5 207 214 10.4046/trd.2013.74.5.207 2-s2.0-84879353986
8. Ewig S., Torres A., Woodhead M., Assessment of pneumonia severity: a European perspective. European Respiratory Journal 2006 27 1 6 8 10.1183/09031936.06.00130205 2-s2.0-30744440695
9. Capelastegui A., España P. P., Quintana J. M., Areitio I., Gorordo I., Egurrola M., Bilbao A., Validation of a predictive rule for the management of community-acquired pneumonia. European Respiratory Journal 2006 27 1 151 157 10.1183/09031936.06.00062505 2-s2.0-30744456545
10. Richards G., Levy H., Laterre P.-F., CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. Journal of Intensive Care Medicine 2011 26 1 34 40 10.1177/0885066610383949 2-s2.0-79251625693
11. Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D. J., Zhang J., Ratajczak J., Ratajczak M. Z., CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. Journal of Molecular Histology 2004 35 3 233 245 10.1023/B:HIJO.0000032355.66152.b8 2-s2.0-7944230945
12. Petty J. M., Sueblinvong V., Lenox C. C., Jones C. C., Cosgrove G. P., Cool C. D., Rai P. R., Brown K. K., Weiss D. J., Poynter M. E., Suratt B. T., Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury. Journal of Immunology 2007 178 12 8148 8157 10.4049/jimmunol.178.12.8148 2-s2.0-34250165460
13. Delano M. J., Kelly-Scumpia K. M., Thayer T. C., Winfield R. D., Scumpia P. O., Cuenca A. G., Harrington P. B., O'Malley K. A., Warner E., Gabrilovich S., Mathews C. E., Laface D., Heyworth P. G., Ramphal R., Strieter R. M., Moldawer L. L., Efron P. A., Neutrophil mobilization from the bone marrow during polymicrobial sepsis is dependent on CXCL12 signaling. Journal of Immunology 2011 187 2 911 918 10.4049/jimmunol.1100588 2-s2.0-79960532406
14. Abi-Younes S., Sauty A., Mach F., Sukhova G. K., Libby P., Luster A. D., The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circulation Research 2000 86 2 131 138 10.1161/01.RES.86.2.131 2-s2.0-0033964318
15. Burgoyne C. H., Field S. L., Brown A. K., Hensor E. M., English A., Bingham S. L., Verburg R., Fearon U., Lawson C. A., Hamlin P. J., Straszynski L., Veale D., Conaghan P., Hull M. A., Van Laar J. M., Tennant A., Emery P., Isaacs J. D., Ponchel F., Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Annals of the Rheumatic Diseases 2008 67 6 750 757 10.1136/ard.2007.073833 2-s2.0-45149093251
16. + cell mobilization after acute myocardial infarction. International Journal of Cardiology 2006 111 2 202 208 10.1016/j.ijcard.2005.06.043 2-s2.0-33746103283
17. Mandell L. A., Wunderink R. G., Anzueto A., Bartlett J. G., Campbell G. D., Dean N. C., Dowell S. F., File T. M. Jr., Musher D. M., Niederman M. S., Torres A., Whitney C. G., Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007 44 2 S27 S72 10.1086/511159 2-s2.0-33847155159
18. Fine M. J., Auble T. E., Yealy D. M., Hanusa B. H., Weissfeld L. A., Singer D. E., Coley C. M., Marrie T. M., Kapoor W. N., A prediction rule to identify low-risk patients with community-acquired pneumonia. The New England Journal of Medicine 1997 336 4 243 250
19. Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E., APACHE II: a severity of disease classification system. Critical Care Medicine 1985 13 10 818 829 10.1097/00003246-198510000-00009 2-s2.0-0022256529
20. Lim W. S., Van Der Eerden M. M., Laing R., Boersma W. G., Karalus N., Town G. I., Lewis S. A., Macfarlane J. T., Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003 58 5 377 382 10.1136/thorax.58.5.377 2-s2.0-0038554228
21. Chalmers J. D., Singanayagam A., Hill A. T., C-reactive protein is an independent predictor of severity in community-acquired pneumonia. The American Journal of Medicine 2008 121 3 219 225 10.1016/j.amjmed.2007.10.033 2-s2.0-39849091058
22. Smith R. P., Lipworth B. J., C-reactive protein in simple community-acquired pneumonia. Chest 1995 107 4 1028 1031 10.1378/chest.107.4.1028 2-s2.0-0028901681
23. Torres A., Ramirez P., Montull B., Menéndez R., Biomarkers and community-acquired pneumonia: tailoring management with biological data. Seminars in Respiratory and Critical Care Medicine 2012 33 3 266 271 10.1055/s-0032-1315638 2-s2.0-84862495531
24. de Jager C. P. C., Wever P. C., Gemen E. F. A., Kusters R., van Gageldonk-Lafeber A. B., van der Poll T., Laheij R. J. F., The neutrophil-lymphocyte count ratio in patients with community-acquired pneumonia. PLoS ONE 2012 7 10 e46561 10.1371/journal.pone.0046561 2-s2.0-84867023405
25. Christ-Crain M., Morgenthaler N. G., Stolz D., Müller C., Bingisser R., Harbarth S., Tamm M., Struck J., Bergmann A., Müller B., Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Critical Care 2006 10 3, article R96 10.1186/cc4955 2-s2.0-34248330207
26. Boussekey N., Leroy O., Georges H., Devos P., D'Escrivan T., Guery B., Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005 33 4 257 263 10.1007/s15010-005-4096-2 2-s2.0-23844548733
27. García Vázquez E., Martínez J. A., Mensa J., Sánchez F., Marcos M. A., de Roux A., Torres A., C-reactive protein levels in community-acquired pneumonia. European Respiratory Journal 2003 21 4 702 705 10.1183/09031936.03.00080203 2-s2.0-0037386251
28. Black S., Kushner I., Samols D., C-reactive protein. The Journal of Biological Chemistry 2004 279 47 48487 48490 10.1074/jbc.R400025200 2-s2.0-10344239447
29. Werner L., Guzner-Gur H., Dotan I., Involvement of CXCR4/CXCR7/CXCL12 interactions in inflammatory bowel disease. Theranostics 2013 3 1 40 46 10.7150/thno.5135 2-s2.0-84883162884
30. Charo I. F., Ransohoff R. M., Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation. The New England Journal of Medicine 2006 354 6 610 621 10.1056/NEJMra052723 2-s2.0-32144454172
31. Kim Y.-S., Bigliani L. U., Fujisawa M., Murakami K., Chang S.-S., Lee H.-J., Lee F. Y., Blaine T. A., Stromal cell-derived factor 1 (SDF-1, CXCL12) is increased in subacromial bursitis and downregulated by steroid and nonsteroidal anti-inflammatory agents. Journal of Orthopaedic Research 2006 24 8 1756 1764 10.1002/jor.20197 2-s2.0-33747029181
32. Sánchez-Martín L., Sánchez-Mateos P., Cabañas C., CXCR7 impact on CXCL12 biology and disease. Trends in Molecular Medicine 2013 19 1 12 22 10.1016/j.molmed.2012.10.004 2-s2.0-84871715854
33. Tsai H.-T., Tee Y.-T., Hsieh Y.-H., Chiou H.-L., Lin C.-W., Tsai H.-C., Wang P.-H., Yang S.-F., Elevated plasma stromal cell-derived factor 1 protein and its gene polymorphism in patients with pelvic inflammatory disease. Reproductive Sciences 2009 16 6 610 617 10.1177/1933719109332829 2-s2.0-65549142128